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Evaluation of the synovial tissue revealed at 15 minutes post-injection
countless numbers of intact RBC that were almost completely disappared
after 48 hours, withonly limited recruitment of macrophages and iron
deposition.
Conclusions: Blood is cleared very rapidly from the canine knee joint, but
in that short time span already has adverse effects on both cartilage and
synovial tissue. This rapid clearance can play a role in the discrepancy
between long-term in vitro and in vivo effects of blood-induced joint
damage since more than 10% v/v blood for 48 hours is needed induced
to long-term adverse effects in vitro. Irrespectively, blood has devastating
effects on articular cartilage very rapidly, and in this respect it is important
to prevent (traumatic) joint haemorrhages and if they occur, to treat them
properly.
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Purpose: Bone morphogenic protein (BMP) activities are controlled in
part by antagonists. In human osteoarthritic (OA) cartilage, the BMP an-
tagonists follistatin and gremlin are increased, but differentially regulated.
Using the OA dog model, we determined if these BMP antagonists were
produced at different stages during the disease process by comparing
their in situ temporal and spatial distribution.
Methods: OA was induced in dogs by sectioning the anterior cruci-
ate ligament. Dogs were sacriﬁced 4 (n = 4), 8 (n = 4), 10 (n = 5) and
12 (n = 4) weeks after surgery, and non-operated (n = 7) dogs served
as normal controls. Cartilage was removed, differentiating ﬁbrillated and
non-ﬁbrillated areas. In situ protein levels of follistatin, gremlin, BMP-2/4
and Il-1b were determined by immunohistochemistry and morphometric
analyses. Growth factor-induced gremlin expression was also assessed
in dog chondrocytes by real-time PCR.
Results: Follistatin and gremlin production was very low in normal carti-
lage. Gremlin was already signiﬁcantly up-regulated in both non-ﬁbrillated
(p< 0.004) and ﬁbrillated (p< 0.02) areas at 4 weeks post-surgery, and
only slightly increased with the progression of the disease. Follistatin
showed a time-dependent increased level in the non-ﬁbrillated areas with
signiﬁcance (p< 0.02) reached at 8−12 weeks; in the ﬁbrillated areas high
levels were already seen at 4 weeks with signiﬁcance reached at each
time point (p< 0.0001). In the whole cartilage, follistatin and Il-1b temporal
production showed similar patterns; this was also true for gremlin and
BMP-2/4, although BMP-2/4 production was already high in the normal
dogs. Data revealed that the basic ﬁbroblast growth factor (bFGF) could
be another factor that increases gremlin early in the disease. Indeed,
bFGF markedly induced gremlin in dog chondrocytes. Moreover, and
although a similar level of bFGF was found in both normal and OA
cartilage, the presence of a marked positive staining in the extracellular
matrix throughout the cartilage layers was found only in the OA cartilage.
Comparison between superﬁcial and deep zones revealed that follistatin
is located mostly in the superﬁcial zone of the cartilage, while gremlin
is produced both in the superﬁcial and deep layers. A similar pattern for
follistatin and Il-1b was found only in the superﬁcial zone, whereas gremlin
and BMP-2/4 had similar proﬁles in both zones.
Conclusions: Data show, for the ﬁrst time, different spatial and temporal
production of gremlin and follistatin in cartilage during the progression
of OA. These data, in addition to the signiﬁcant up-regulation of gremlin
earlier than follistatin, strongly suggest that gremlin is involved during
the early/remodeling phases, and follistatin linked to the inﬂammatory
process of the disease. These ﬁndings may reﬂect different roles for each
antagonist in this disease.
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Purpose: The STR/ort mice develop spontaneous osteoarthritis (OA) of
the knee, and are believed to be a relevant model for human knee OA.
We have recently shown that treatment with glucosamine sulfate reduced
the severity of the OA histological score as well as histomorphometric
parameters in this strain. To further validate this model for drug discovery
purposes, we investigated its responsivity to further interventions believed
to be effective in either murine or human OA. While administration of the
selective Cox-2 inhibitor celecoxib has been shown to be effective on the
symptoms of human OA, it has been recently demonstrated that deletion
of aggrecanase-2 protects mice from cartilage degeneration in surgically-
induced OA. Therefore we investigated in two separate studies the effects
of celecoxib or of a speciﬁc aggrecanase inhibitor (CR 4152), respectively,
in STR/ort mice.
Methods: STR/ort male mice were recruited at 5 months of age
(n = 20−22). One group of animals was sacriﬁced at this age and served
as a “baseline” control. Celecoxib (10 and 30mg/kg b. w.) was admin-
istered orally once daily 3 for months, while CR 4152 (10 and 30mg/kg
of b.w.) was administered subcutaneously once daily for 3 months. At
the end of treatment, the animals were euthanized and the knee joints
collected, processed for histology and blindly scored according to both
Mankin’s and the OARSI method. Furthermore, in the CR 4152 study, a
histomorphometric analysis was performed on the medial tibial plateau,
measuring the parameters of cartilage volume and lesion surface, with
the operator still blinded to the experimental groups. Statistical analysis
was performed by the Student’s t test or by ANOVA followed by Dunn’s
or Dunnett’s tests comparing all treatment groups vs. vehicle.
Results: After three months of daily treatment, we observed that vehicle-
treated animals displayed severe OA with clefting and erosion of the
articular cartilage to the subchondral bone, with prominent chondro-
osseous metaplasias and often inﬂammation and pannus. OA grade ×
stage score of the medial tibial plateau was signiﬁcantly higher in vehicle
vs. naive 5-month (baseline) mice. In the celecoxib 30mg/kg group there
was only a trend for a decrease of the OA grade × stage score that was
far from statistical signiﬁcance (p = 0.648, Figure 1). Conversely, the OA
grade × stage score was signiﬁcantly decreased in the CR 4152 30mg/kg
group compared to vehicle (Figure 2).
Figure 1. OARSI scoring method (grade × stage, median); celecoxib
group.
Figure 2. OARSI scoring method (grade × stage, median); CR 4152
group.
